{"title":"Combining topiramate with prolonged exposure therapy improves PTSD symptoms","authors":"","doi":"10.1002/pu.31320","DOIUrl":"https://doi.org/10.1002/pu.31320","url":null,"abstract":"<p>Military veterans with comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) who received topiramate in combination with prolonged exposure therapy (PE) showed greater improvement in PTSD symptoms than those receiving PE alone, a new study has found. The combination treatment did not lead to significant improvement in alcohol use outcomes compared with PE alone. Study results were published online March 19, 2025, in the <i>American Journal of Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Microdosing of LSD does not show efficacy in adults with ADHD","authors":"","doi":"10.1002/pu.31324","DOIUrl":"https://doi.org/10.1002/pu.31324","url":null,"abstract":"<p>Microdosing of lysergic acid diethylamide (LSD) over a 6-week period showed no significant benefits over placebo in reducing symptoms of attention-deficit hyperactivity disorder (ADHD) in adults, a Phase 2A trial has found. Both the LSD and placebo groups experienced marked improvement, the investigators reported.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review of GLP-1 trials finds low incidence of suicide risk","authors":"","doi":"10.1002/pu.31321","DOIUrl":"https://doi.org/10.1002/pu.31321","url":null,"abstract":"<p>A systematic review and meta-analysis comprising 27 trials comparing glucagon-like peptide 1 (GLP-1) receptor agonists and placebo in patients with type 2 diabetes or obesity found no significantly increased risk of suicidal behavior in conjunction with the popular medications. The incidence of suicide and self-harm was very low in both the GLP-1 and placebo groups. Results of the review were published online March 19, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Climate change and psychopharmacology","authors":"Lawrence H. Price M.D.","doi":"10.1002/pu.31327","DOIUrl":"https://doi.org/10.1002/pu.31327","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Heatwaves exacerbate risk of illnesses in patients with mental health conditions","authors":"","doi":"10.1002/pu.31326","DOIUrl":"https://doi.org/10.1002/pu.31326","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Greater anticholinergic burden associated with poorer cognition in patients with psychosis","authors":"","doi":"10.1002/pu.31325","DOIUrl":"https://doi.org/10.1002/pu.31325","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Quetiapine augmentation more effective than lithium in treatment-resistant depression trial","authors":"","doi":"10.1002/pu.31328","DOIUrl":"https://doi.org/10.1002/pu.31328","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-world usage of paliperidone palmitate injection","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31322","DOIUrl":"https://doi.org/10.1002/pu.31322","url":null,"abstract":"<p>A challenge in achieving clinical remission in patients with schizophrenia lies in the high rate of antipsychotic discontinuation, often resulting in relapse, characterized by exacerbation of symptomatology, deterioration in functional activities, and the emergence of treatment resistance. Long-acting antipsychotics have been developed to help reduce medication nonadherence and minimize relapse. One of the most widely used of these drugs is paliperidone palmitate, a long-acting injectable (LAI) formulation of paliperidone (an active metabolite of risperidone).</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Study documents risk of thyroid, kidney complications from lithium treatment","authors":"","doi":"10.1002/pu.31329","DOIUrl":"https://doi.org/10.1002/pu.31329","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Data on prescription stimulant misuse suggest need for closer screening","authors":"","doi":"10.1002/pu.31323","DOIUrl":"https://doi.org/10.1002/pu.31323","url":null,"abstract":"<p>Among U.S. adults aged 18 to 64 who reported using prescription stimulant medications, around one-quarter reported stimulant misuse and 9% reported stimulant use disorder, according to a new study. Stimulant misuse and stimulant use disorder were substantially more common among individuals using amphetamines than among those using methylphenidate.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}